Relative Bioavailability Study of HR19042 in Healthy Subjects

NCT06922305 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy; Autoimmune Hepatitis

Interventions

DRUG: HR19042 Capsule, Tarpeyo®, Budenofalk®

Sponsor

Jiangsu HengRui Medicine Co., Ltd.